Hyderabad-based drugs firm Dr Reddy?s Laboratories (DRL) today said it has launched its generic version of Swiss pharma major Novartis? diabetes treatment drug ?Starlix? in the US market.
The generic version of Starlix, known as nateglinide, is used for treating type 2 diabetes by stimulating release of insulin from the pancreas.
?We got the approval on September 9 and the product (nateglinide) has been launched in the US,? a company spokesperson said.
The spokesperson, however, did comment on the details.
Industry estimates put the annual sales of Starlix around USD 120 million to USD 150 million.
Shares of DRL closed at Rs 820.55 at the Bombay Stock Exchange, 1.4 per cent higher from previous day?s closing.